Sugi Predict

Sugi Predict / Compounds / SCHEMBL15328409

SCHEMBL15328409

SCHEMBL15328409

CC1(C)OB(c2ccc3c(cnn3C3COC3)c2)OC1(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 1/20 0.44
▸ LPL P06858 9/20 0.35
▸ LIPG Q9Y5X9 9/20 0.35
▸ TNKS O95271 2/20 0.34
▸ PDE1B Q01064 1/20 0.33
▸ PDE1C Q14123 1/20 0.33
▸ FFAR1 O14842 1/20 0.33
▸ DGAT1 O75907 1/20 0.32
▸ CA12 O43570 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA3 P07451 1/20 0.32
▸ CA4 P22748 1/20 0.32
▸ CA6 P23280 1/20 0.32
▸ CA5A P35218 1/20 0.32
▸ CA7 P43166 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ CA14 Q9ULX7 1/20 0.32
▸ CA5B Q9Y2D0 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30613534 0.90 LRRK2 (0.39) IRAK4TNKSLRRK2ABCG2
SCHEMBL29041937 0.90 LRRK2 (0.39) IRAK4TNKSLRRK2ABCG2
SCHEMBL17678304 0.90 IRAK4 (0.46) IRAK4LPLLIPGTNKSFFAR1
SCHEMBL30122296 0.88 IRAK4 (0.42) IRAK4TNKSPDE1BPDE1CMAPK1
SCHEMBL28956488 0.88 IRAK4 (0.42) IRAK4TNKSPDE1BPDE1CMAPK1
SCHEMBL17678315 0.88 IRAK4 (0.44) IRAK4LPLLIPGTNKSFFAR1
SCHEMBL10060453 0.85 IRAK4 (0.42) IRAK4LPLLIPGTNKSFFAR1
SCHEMBL31757685 0.81 IRAK4 (0.46) IRAK4LRRK2ABCG2
SCHEMBL15328646 0.80 IRAK4 (0.34) IRAK4FFAR1DGAT1LRRK2
SCHEMBL15328807 0.80 PDE1B (0.35) IRAK4PDE1BPDE1CLRRK2ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021465-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-06-01 — — US disclosed
US-11008305-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-05-18 — — US disclosed
EP-3459942-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2020-12-30 — — EP disclosed
CN-106977495-B DNA-PK inhibitors 沃泰克斯药物股份有限公司 2020-08-04 — — CN disclosed
US-20200109130-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2020-04-09 — — US disclosed
US-20200062732-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2020-02-27 — — US disclosed
CN-106986863-B DNA-PK inhibitors 沃泰克斯药物股份有限公司 2019-12-31 — — CN disclosed
US-10442791-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-10-15 — — US disclosed
US-10391095-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-08-27 — — US disclosed
EP-3459942-A1 DNA-PK INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2019-03-27 — — EP disclosed
US-20160250212-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-09-01 — — US disclosed
EP-3057959-A1 DNA-PK INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2016-08-24 — — EP disclosed
US-9376448-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-06-28 — — US disclosed
US-9296701-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-03-29 — — US disclosed
US-20150111871-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-04-23 — — US disclosed
WO-2015058031-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-04-23 — — WO disclosed
EP-2841428-A1 DNA-PK INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2015-03-04 — — EP disclosed
US-20140045869-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2014-02-13 — — US disclosed
WO-2013163190-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICAL INCORPORATED (US) 2013-10-31 — — WO disclosed
US-20130281431-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2013-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045869-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-20200109130-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-20160250212-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-11008305-B2 DNA-PK inhibitors POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-20150111871-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-10442791-B2 DNA-PK inhibitors POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-20200062732-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-20130281431-A1 DNA-PK INHIBITORS POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-10391095-B2 DNA-PK inhibitors POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885
US-11021465-B2 DNA-PK inhibitors POLK, DTYMK, DCK IRAK4 1215/4885LPL 2656/4885LIPG 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.